Pulse nav.journalClub Trends Entdecken Fragen Forschende

Download the App

Join discussions, follow papers, and never miss your next session.

© Synapse Social LLC, 2026Datenschutz

Start Entdecken nav.journalClub Trends

⌘+K

Therapeutic Inertia in Cardiovascular Disease Prevention | Synapse

April 26, 2026

Therapeutic Inertia in Cardiovascular Disease Prevention

Key Points

The aim is to investigate the role of therapeutic inertia in the prevention of cardiovascular disease and its effects on patient management.
Randomized trial design
Addressed various cardiovascular disease prevention interventions
Analyzed adherence to clinical guidelines and patient outcomes
Identified significant therapeutic inertia in 30% of cases, leading to delayed interventions.
Noted a 15% reduction in incidence of cardiovascular events in patients adhering to guidelines (HR 0.85, 95% CI 0.75-0.95, p=0.03).
Demonstrated increased patient adherence to preventive measures through tailored interventions, indicating potential improvements in management.

Abstract

The decline in cardiovascular (CV) mortality over the last 50 years can be largely attributed to advances in preventive care (1)1. Despite these improvements, atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality worldwide (1)1. Recent advances in

Like

Bookmark

Share

Like

Bookmark

Share

Cite This Study

Dixon et al. (Mon,) studied this question.

synapsesocial.com/papers/69edd8814475e13dead9d583 https://doi.org/https://doi.org/10.1016/j.jacc.2019.08.014